52 yrs old female started rashes all over the body and loss of whole body hair and scalp hair loss what is the cause
52 year old female generalized rash total body hair loss alopecia causes diagnosis
"Of patients with alopecia areata, 5% develop hair loss of their entire scalp hair (alopecia areata totalis) and 1% develop alopecia areata universalis (loss of total body hair)." - Fitzpatrick's Dermatology
"Secondary syphilis results in a characteristic maculopapular rash involving the palms and soles, alopecia, oral mucous patches, or condyloma latum." - Goldman-Cecil Medicine
"Non-scarring alopecia - diffuse thinning or hair fragility" is one of the classic diagnostic criteria for SLE - Rosen's Emergency Medicine / Harrison's
| Drug class | Mechanism |
|---|---|
| Chemotherapy agents | Anagen effluvium - rapid, complete hair loss |
| Retinoids (isotretinoin, acitretin) | Diffuse telogen effluvium + skin irritation |
| Ribavirin (hepatitis C treatment) | Alopecia + rash are listed adverse effects |
| Targeted cancer therapies (EGFR inhibitors) | Acneiform rash + alopecia |
| Anticoagulants, antithyroid drugs | Hair loss |
"Glucagon-secreting NETs of the pancreas are associated with a characteristic rash and glucose intolerance. They develop primarily in patients over the age of 50 with a slight female predominance." - Yamada's Textbook of Gastroenterology
| Test | Purpose |
|---|---|
| TSH, Free T4 | Hypothyroidism |
| ANA, anti-dsDNA, complement | SLE |
| RPR/VDRL + TPHA | Syphilis |
| CBC, CMP, LFTs | General screen |
| Zinc, iron studies, ferritin | Nutritional deficiency |
| Skin biopsy of rash + scalp | Histopathology - scarring vs. non-scarring alopecia |
| Dermoscopy | Alopecia areata (exclamation point hairs, yellow dots) |
| Glucagon level (if rash is migratory/erosive) | Glucagonoma |
| Medication review | Drug-induced |
Sources: Fitzpatrick's Dermatology 9e, Goldman-Cecil Medicine, Harrison's Principles 22e, Rosen's Emergency Medicine, Yamada's Gastroenterology
Treatment for this
alopecia universalis treatment JAK inhibitor
PMID: 39328096
Treatment depends on the confirmed underlying cause. The approach below covers each key diagnosis.
| Drug | Dose | Approval Status |
|---|---|---|
| Baricitinib (Olumiant) | 2-4 mg daily | FDA-approved for severe alopecia areata |
| Ritlecitinib (Litfulo) | 50 mg daily (with optional 200 mg loading x4 weeks) | FDA-approved for AA in patients ≥12 years |
| Tofacitinib | 5-10 mg twice daily | Off-label use |
| Ruxolitinib | 10-20 mg twice daily | Off-label use |
| Cause | First-Line Treatment | Expected Hair Regrowth |
|---|---|---|
| Alopecia universalis | Baricitinib or Ritlecitinib (JAK inhibitors) | Partial-complete in 6-12 months; maintenance required |
| Secondary syphilis | Benzathine penicillin G IM | Full recovery in months |
| SLE | Hydroxychloroquine | Partial; depends on disease control |
| Drug-induced | Stop offending drug | Full recovery in 3-6 months |
| Hypothyroidism | Levothyroxine | Significant improvement in 3-6 months |
Sources: Goldman-Cecil Medicine, Fitzpatrick's Dermatology 9e, Dermatology 2-Volume Set 5e, Goodman & Gilman's Pharmacology; Mesinkovska et al., J Dermatol 2024, PMID 39328096; King et al., J Am Acad Dermatol 2025, PMID 39447758